What is Retatrutide?
Retatrutide, also known by its development code LY3437943, is a synthetic single-chain peptide investigated as a triple hormone-receptor agonist with activity at the GIP, GLP-1, and glucagon receptors. It is supplied as a lyophilized powder for in-vitro laboratory research use only.
Retatrutide research
Published work on Retatrutide is qualitative in the framing below. Each item describes the focus of the research itself, not an outcome for any person.
- Energy metabolism and body-weight regulation. Retatrutide has been the subject of animal and clinical studies exploring its role in models of energy balance and body-weight regulation.
- Glucose handling. Studies have examined the compound in research contexts related to glucose handling and metabolic signaling.
- Triple-agonist mechanism. Research has characterized the combined engagement of the GIP, GLP-1, and glucagon receptors by a single molecule.
- Hepatic and adipose research. Investigations have looked at endpoints such as hepatic fat content within study populations, alongside adipose-tissue measures.
Retatrutide specifications
| CAS Number | 2381089-83-2 |
|---|---|
| Synonyms | LY3437943, GGG tri-agonist |
| Molecular Formula | Provided on batch COA |
| Molecular Weight | Provided on batch COA |
| Sequence | Proprietary / provided on batch COA |
| Purity | ≥99% by HPLC |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in bacteriostatic or sterile water |
| Storage | Store lyophilized at -20°C; protect from light |
| Shelf Life | 24+ months lyophilized at -20°C |
| Presentation | 12 mg or 24 mg per vial |
Retatrutide reconstitution & storage
Store the sealed lyophilized vial at -20°C. Reconstitute with bacteriostatic or sterile water by directing the stream against the vial wall; do not shake. After reconstitution, store refrigerated at 2 to 8°C and use within the period indicated on the batch COA. For laboratory research handling only.
Retatrutide certificate of analysis (COA)
A batch-specific Certificate of Analysis accompanies every order. The COA documents identity and purity by HPLC for the lot you receive, along with the molecular data listed as provided on batch COA above. Third-party analytical reports are available on request.
Retatrutide research references
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023. PubMed
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in people with type 2 diabetes: a phase 2 trial. The Lancet. 2023. PubMed
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism. 2022. PubMed
Retatrutide FAQ
What is Retatrutide (LY3437943)?
Retatrutide, development code LY3437943, is a synthetic single-chain peptide investigated as a triple hormone-receptor agonist with activity at the GIP, GLP-1, and glucagon receptors. It is supplied as a lyophilized powder for in-vitro laboratory research use only.
What purity does PeptideX1 Retatrutide meet?
Each batch is ≥99% purity by HPLC, verified per batch on the accompanying Certificate of Analysis.
Is a Certificate of Analysis included?
Yes. A batch-specific Certificate of Analysis is included with every order.
How is it shipped and stored?
It ships lyophilized, sealed and desiccated. Store the sealed vial at -20°C and protect it from light.
Is retatrutide similar to Ozempic or tirzepatide?
Retatrutide (LY3437943) is a research peptide studied as a triple GIP, GLP-1, and glucagon receptor agonist, a broader mechanism than single GLP-1 agonists such as semaglutide (marketed as Ozempic) or the dual agonist tirzepatide. PeptideX1 supplies retatrutide strictly for in-vitro laboratory research. It is not a weight-loss product and not a substitute for any prescription medication.
Is this product for human use?
No. It is sold strictly for in-vitro laboratory research use only. It is not for human or veterinary use.